Regulated manufacturing, hospital field trials, and regulatory filings now underway with Ebulent Medical in ShenzhenLAS VEGAS, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) (“CBSC” or the “Company”), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, today provided an update on the execution of its China market entry plan for its MyCardia AT cardiac event monitoring device. The Company has formally initiated manufacturing and re ...

Core Insights - Cardiac Biotech Solutions, Inc. has entered into a five-year exclusive distribution agreement with Noventis Medical for its non-invasive cardiac monitoring products in Costa Rica, Panama, Colombia, and Argentina [1][2][3] - The contract value for the distribution rights is set at $600,000 USD, with Noventis Medical also granted a right of first refusal for future distribution opportunities in other Central and South American countries [2][3] Company Developments - The CEO of Cardiac Biotech Solutions expressed enthusiasm about expanding international presence and strengthening market reach in Latin America through this partnership [3] - Noventis Medical aims to provide reliable solutions for heart issue identification in the Latin American market, addressing the high prevalence of cardiovascular disease in the region [3] - The company continues to advance the global commercialization of its MyCardia AT event monitoring platform, which features lightweight wearable technology and cloud-based connectivity [3][5] Product Information - MyCardia AT integrates mobile applications for iOS, Android, and WeChat, enhancing patient compliance and providing accurate information for physicians [5] - The company has secured regulatory clearance in the U.S. and is progressing with submissions in Canada and China, marking significant milestones in its mission to deliver advanced cardiac monitoring solutions [3]